Taken together, these findings reveal an opportunity to treat multiple age-related diseases, including neurodegenerative disorders, obesity, diabetes, arthritis, and atherosclerosis, with a single MT1-MMP-blocking agent. This evidence concerns the gene MMP14 and atherosclerosis.